FibroGen International announced the completion of the sale of FibroGen China to AstraZeneca.
The total consideration for the transaction was approximately $220 million, with $85 million in enterprise value and $135 million in net cash held in China.
The company also repaid its senior secured term loan facilities with Morgan Stanley Tactical Value for about $81 million.
Transaction Details
Sale of FibroGen China to AstraZeneca for $220 million including $85 million in enterprise value and $135 million in cash.
Loan Repayment
Repayment of senior secured term loan facilities with Morgan Stanley Tactical Value for approximately $81 million.
Related Agreements
Entered into related transaction agreements including a transition services agreement at the closing.
- The unaudited pro forma condensed consolidated financial information provided in the filing illustrates the effects of the completed sale and loan repayment on FibroGen's financial statements.
- The transaction adjustments include sale and revenue recognition related to FibroGen China, post-closing services income, and loan repayment impact.
- Management's assumptions were used to prepare the pro forma financial information, which may differ from the final accounting treatment.
The sale of FibroGen China marks a significant strategic move for FibroGen, leading to a reshaping of its financial structure and positioning in the market.